<DOC>
	<DOCNO>NCT00004861</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different way may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness gemcitabine without CI-994 treat patient advanced pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without CI-994 Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy safety CI-994 give combination gemcitabine compare gemcitabine alone treatment patient advance pancreatic cancer . OUTLINE : Gemcitabine standard care pancreatic cancer administer intravenous injection . Patients receive gemcitabine week 3 week follow 1 week rest . Patients take capsule ( placebo investigational chemotherapy ) daily 21 consecutive day begin first gemcitabine infusion . The duration treatment determine patient 's tolerance therapy assessment disease response . PROJECTED ACCRUAL : A total 172 patient enrol Canada , Europe , United States competitive basis .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic cytologic diagnosis advance ( stage II III ) metastatic ( stage IV ) adenocarcinoma exocrine pancreas consider surgical candidate Measurable unmeasurable disease PATIENT CHARACTERISTICS : Age : Age great equal 18 year Performance status : Karnofsky 70100 % Life expectancy : Expected survival great 12 week Hematopoietic : No inadequate bone marrow function within 2 week prior randomization evidence follow : Absolute neutrophil count le 2000/mm3 Platelet count le 100,000/mm3 Hepatic : No inadequate hepatic function within 2 week prior randomization evidence follow : Total bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( great 5 time ULN liver metastasis document ) Renal : No inadequate renal function within 2 week prior randomization evidence follow : Creatinine clearance le 50 mL/min Other : Adequate IV access receive gemcitabine infusion Capable swallow intact study medication capsule Capable give informed consent Capable following instruction daily caregiver assume responsibility administer study medication complete medication diaries No life threaten illness ( unrelated tumor ) No woman childbearing potential unless use acceptable method contraception , pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Prior immunotherapy biologic therapy may allow , must complete least 1 month prior randomization Chemotherapy : No prior chemotherapy advance stage pancreatic cancer Fluorouracil ( without leucovorin calcium interferon ) give radiation radiation sensitizer may allow , must complete least 3 month prior randomization Endocrine therapy : Prior hormonal therapy may allow , must complete least 1 month prior randomization Radiotherapy : No radiation therapy within 4 week prior first treatment Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>